false000081868600-000000000008186862026-11-172026-11-17

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 17, 2026

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

 

 

Israel

 

001-16174

 

Not Applicable

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

 

400 Interpace Parkway, #3

Parsippany NJ, 07054 USA

+1-973-658-0301

(Address of principal executive offices, zip code and telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary Shares, par value NIS 0.1 per share

 

TEVA

 

New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer

On November 17, 2026, Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, notified Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) of his intention to resign. Dr. Hughes will step down immediately from his role and will continue to assist with a smooth transition over the next few months.

 

ITEM 7.01

Regulation FD Disclosure

On November 18, 2026, Teva issued a press release announcing that Dr. Eric Hughes will be leaving Teva. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act, except as set forth by specific reference in such filing.

 


ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

 

 

 

Exhibit

 

Description of Document

 

 

99.1

 

Press release of the Company issued on November 18, 2026.

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

 

 

 

 

 

Date: November 18, 2026

By:

/s/ Eli Kalif

 

 

 

 

 

Name: Eli Kalif

 

 

Title: Executive Vice President,

 

 

            Chief Financial Officer